Skip to main content

Publications & Presentations

Publications & Presentations

Can AI-Driven Cancer Care Help Improve Mental Well-Being?

AI-enabled predictive and prognostic tests allow clinicians a line of sight.

Read more

Publications & Presentations

ArteraAI Validates its Prognostic Model in Advanced Prostate Cancer

ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announces [...]

Read more

Publications & Presentations

AI biomarker predictive of long-term ADT benefit in patients with prostate cancer

Investigators have validated the first AI-derived predictive biomarker of long-term androgen deprivation therapy (ADT) benefi [...]

Read more

Publications & Presentations

The Vital Role of Clinical Validation in the Adoption of AI within Healthcare

The healthcare industry has witnessed a significant surge in interest and opportunity to integrate artificial intelligence (A [...]

Read more

Publications & Presentations

ASCO 2023: Discussant: Hitting the Sweet Spot with Radiation and Androgen Deprivation

Following earlier presentations by Dr. Alberto Bossi (PEACE-1 radiotherapy results), Dr. Andrew Armstrong (ArteraAI long-term [...]

Read more

Publications & Presentations

Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer

ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced the pub [...]

Read more

Publications & Presentations

ASCO 2023: Digital Histopathology-Based Multimodal Artificial Intelligence Scores Predict Risk of Progression in a Randomized Phase III Trial in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

Dr. Felix Feng presented on the use of digital histopathology-based multimodal artificial intelligence scores to predict risk [...]

Read more

Publications & Presentations

ASCO 2023: AI-Derived Digital Pathology Biomarker Predicts Benefit of Long-Term ADT with Radiotherapy in Localized High-Risk Prostate Cancer

Dr. Andrew J. Armstrong presented the results of a pooled analysis of multiple phase III NRG/RTOG trials aimed at developing [...]

Read more

Publications & Presentations

ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker at 2023 ASCO Annual Meeting

The biomarker is the first to predict long-term ADT usage in men with high-risk localized prostate cancer.

Read more

1 2 3